Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study
BackgroundThe concomitant use of nirmatrelvir/ritonavir and voriconazole is generally contraindicated in clinical practice because of drug‒drug interactions (DDIs). However, emerging clinical data suggest that this DDI is complicated and that the concomitant use of these two drugs may be feasible.Me...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-08-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1654671/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|